Literature DB >> 30207560

Value of Serum Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen in Evaluating Severity and Prognosis of Connective Tissue Disease-Associated Interstitial Lung Disease.

Qian Jin1, Jisheng Zheng1, Xianrong Xu1, Yeming Hu2, Ying Zhou1, Weihua Xu1, Feihua Huang1.   

Abstract

OBJECTIVES: This study aims to detect serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) levels in connective tissue disease-associated interstitial lung disease (CTD-ILD) patients and to demonstrate their values in evaluating the severity and prognosis of CTD-ILD. PATIENTS AND METHODS: The study included 82 CTD-ILD patients (54 males, 28 females; mean age 67.9 years; range 29 to 91 years) and 82 controls (54 males, 28 females; mean age 68.1 years; range 30 to 92 years). Patients were followed-up for 12 months. Correlations of serum CEA and CA 19-9 with disease severity parameters (pulmonary function, oxygenation index and involvement score on high resolution computed tomography) were analyzed. Survival analysis was used to evaluate significance of serum CEA and CA 19-9 as prognosis predictors.
RESULTS: Serum CEA and CA 19-9 levels were higher in CTD-ILD patients compared with controls (both p<0.05) and correlated with disease severity (p<0.05 for all R2). High levels of serum CEA and CA 19-9 were associated with poor survival (both p<0.05). Serum CEA level was indicated as a prognostic factor for cumulative survival (hazard ratio=1.685, 95% confidence interval: 1.405-2.021, p=0.001).
CONCLUSION: In CTD-ILD patients, serum CEA and CA 19-9 are elevated and can be indicators of disease severity. Moreover, serum CEA is a significant and independent predictor of survival.

Entities:  

Keywords:  Carbohydrate antigen 19-9; carcinoembryonic antigen; connective tissue diseases; interstitial lung diseases; prognosis

Year:  2017        PMID: 30207560      PMCID: PMC6117141          DOI: 10.5606/ArchRheumatol.2018.6419

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  29 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis.

Authors:  G A Margaritopoulos; M Romagnoli; V Poletti; N M Siafakas; A U Wells; K M Antoniou
Journal:  Eur Respir Rev       Date:  2012-03-01

Review 3.  Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group.

Authors:  Dinesh Khanna; Shikha Mittoo; Rohit Aggarwal; Susanna M Proudman; Nicola Dalbeth; Eric L Matteson; Kevin Brown; Kevin Flaherty; Athol U Wells; James R Seibold; Vibeke Strand
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

4.  Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate presence of cancer.

Authors:  Samuel Bergamaschi; Edelton Morato; Maria Bazzo; Fabricio Neves; Sonia Fialho; Glaucio Castro; Adriana Zimmermann; Ivanio Pereira
Journal:  Int J Rheum Dis       Date:  2011-09-22       Impact factor: 2.454

5.  Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology.

Authors:  C Vancheri; M Failla; N Crimi; G Raghu
Journal:  Eur Respir J       Date:  2010-03       Impact factor: 16.671

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Carcinoembryonic antigen in bronchoalveolar lavage fluid in patients with idiopathic pulmonary fibrosis.

Authors:  H Takahashi; T Nukiwa; R Matsuoka; T Danbara; H Natori; T Arai; S Kira
Journal:  Jpn J Med       Date:  1985-08

8.  Idiopathic diffuse interstitial pulmonary fibrosis (fibrosing alveolitis), atypical epithelial proliferation and lung cancer.

Authors:  R Haddad; D Massaro
Journal:  Am J Med       Date:  1968-08       Impact factor: 4.965

9.  Structure of alveolar epithelial cells in patients with fibrotic lung disorders.

Authors:  O Kawanami; V J Ferrans; R G Crystal
Journal:  Lab Invest       Date:  1982-01       Impact factor: 5.662

10.  Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis?

Authors:  V Navaratnam; N Ali; C J P Smith; T McKeever; A Fogarty; R B Hubbard
Journal:  Respir Med       Date:  2011-09-15       Impact factor: 3.415

View more
  7 in total

1.  [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].

Authors:  Y Z Gan; Y H Li; L H Zhang; L Ma; W W He; Y B Jin; Y An; Z G Li; H Ye
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

2.  Association of Interstitial Lung Disease With Clinical Characteristics of Chinese Patients With Systemic Lupus Erythematosus.

Authors:  Yaling Chen; Yanqing Wang; Xiangfang Chen; Huishun Liang; Xuwei Yang
Journal:  Arch Rheumatol       Date:  2020-01-08       Impact factor: 1.472

3.  Correlation between serum carbohydrate antigen 19-9 levels and computed tomography severity score in patients with nontuberculous mycobacterial pulmonary disease.

Authors:  Kangjoon Kim; Seung Hyun Yong; Su Hwan Lee; Sang Hoon Lee; Ah Young Leem; Song Yee Kim; Kyungsoo Chung; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Hye-Jeong Lee; Young Ae Kang
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

4.  A Matrix Prediction Model for the 6-Month Mortality Risk in Patients With Anti-Melanoma Differentiation-Associated Protein-5-Positive Dermatomyositis.

Authors:  Zhi-Ming Ouyang; Jian-Zi Lin; Ao-Juan Tang; Ze-Hong Yang; Li-Juan Yang; Xiu-Ning Wei; Qian-Hua Li; Jin-Jian Liang; Dong-Hui Zheng; Bing-Peng Guo; Gui Zhao; Qian Han; Lie Dai; Ying-Qian Mo
Journal:  Front Med (Lausanne)       Date:  2022-04-01

5.  Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity.

Authors:  Qiuhe Chen; Long Qian
Journal:  Contrast Media Mol Imaging       Date:  2022-07-30       Impact factor: 3.009

6.  The significance of elevated tumor markers among patients with interstitial lung diseases.

Authors:  Byoung Soo Kwon; Eun Sun Kim; Sung Yoon Lim; Myung Jin Song; Yeon Wook Kim; Hyung-Jun Kim; Yeon Joo Lee; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Jae Ho Lee
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

7.  A case of raised CA 19-9 in a patient with desmoplastic fibroblastoma of the upper limb.

Authors:  Kumaran Rasappan; Leanne Kayla Rebecca Mei-Yi Shaw; Lester Wai Mon Chan; Khoon Leong Chuah; Mathew Hern Wang Cheng
Journal:  Int Cancer Conf J       Date:  2021-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.